Introduction: Previous studies showed that the combination of peritoneal dialysis (PD) and once-weekly hemodialysis is associated with lower all-cause and cardiovascular mortality. This study aimed to compare the incidence of encapsulating peritoneal sclerosis (EPS) and infection-related mortality among those on combination therapy and those on PD alone. Methods: This prospective study on the Japanese Renal Data Registry included patients on PD from 2010 to 2014. Subjects were followed up until the end of 2015. Exposure of interest was combination therapy compared with PD alone. Patients who transitioned to combination therapy were matched with those on PD alone by propensity scores. Outcomes were EPS and infection-related mortality. Data were analyzed using Cox regression models. Results: Among the matched cohort, 608 and 869 patients were on combination therapy and on PD alone, respectively. Dialysate-to-plasma creatinine (D/P Cr) ratio decreased over time among those on combination therapy, while the ratio increased among those on PD alone (p = 0.01 by the mixed-effects model). During a median follow-up of 2.5 years, 33 experienced EPS and 55 died of infection. Combination therapy was associated with lower infection-related mortality (HR [95% CI]: 0.52 [0.28–0.95]) but not with EPS (HR: 1.21 [0.61–2.40]). Lower mortality was not limited to intra-abdominal infection but also observed for pulmonary infection. Sensitivity analyses considering the effects of dialysis facilities yielded similar results. Conclusions: Combination therapy was associated with lower infection-related mortality. It was also associated with a decline in the D/P Cr ratio over time but not with lower incidence of EPS during the short observation period.

1.
Fukui
H
,
Hara
S
,
Hashimoto
Y
,
Horiuchi
T
,
Ikezoe
M
,
Itami
N
, et al.
Review of combination of peritoneal dialysis and hemodialysis as a modality of treatment for end-stage renal disease
.
Ther Apher Dial
.
2004 Feb
;
8
(
1
):
56
61
. .
2.
Maruyama
Y
,
Yokoyama
K
,
Nakayama
M
,
Higuchi
C
,
Sanaka
T
,
Tanaka
Y
, et al.
Combined therapy with peritoneal dialysis and hemodialysis: a multicenter retrospective observational cohort study in Japan
.
Blood Purif
.
2014 Nov
;
38
(
2
):
149
53
. .
3.
Masakane
I
,
Hasegawa
T
,
Ogata
S
,
Kimata
N
,
Nakai
S
,
Hanafusa
N
, et al.
Peritoneal dialysis registry with 2013 survey report
.
Ther Apher Dial
.
2016 Dec
;
20
(
6
):
557
68
. .
4.
Kawanishi
H
,
Hashimoto
Y
,
Nakamoto
H
,
Nakayama
M
,
Tranaeus
A
.
Combination therapy with peritoneal dialysis and hemodialysis
.
Perit Dial Int
.
2006 Mar–Apr
;
26
(
2
):
150
4
. .
5.
Hoshi
H
,
Nakamoto
H
,
Kanno
Y
,
Takane
H
,
Ikeda
N
,
Sugahara
S
, et al.
Long-term follow-up of patients treated with a combination of continuous ambulatory peritoneal dialysis and hemodialysis
.
Adv Perit Dial
.
2006
;
22
:
136
40
.
6.
Matsuo
N
,
Yokoyama
K
,
Maruyama
Y
,
Ueda
Y
,
Yoshida
H
,
Tanno
Y
, et al.
Clinical impact of a combined therapy of peritoneal dialysis and hemodialysis
.
Clin Nephrol
.
2010 Sep
;
74
(
3
):
209
16
. .
7.
Tanaka
M
,
Mise
N
,
Nakajima
H
,
Uchida
L
,
Ishimoto
Y
,
Kotera
N
, et al.
Effects of combination therapy with peritoneal dialysis and hemodialysis on left ventricular hypertrophy
.
Perit Dial Int
.
2011 Sep–Oct
;
31
(
5
):
598
600
. .
8.
Kanda
R
,
Io
H
,
Nakata
J
,
Makita
Y
,
Sasaki
Y
,
Matsumoto
M
, et al.
Evaluation of long-term combination therapy with peritoneal dialysis and hemodialysis
.
Ther Apher Dial
.
2017 Apr
;
21
(
2
):
180
4
. .
9.
Murashima
M
,
Hamano
T
,
Abe
M
,
Masakane
I
.
Combination of once-weekly haemodialysis with peritoneal dialysis is associated with lower mortality compared with peritoneal dialysis alone: a longitudinal study
.
Clin Kidney J
.
2020
. .
10.
Nataatmadja
MS
,
Johnson
DW
,
Pascoe
EM
,
Darssan
D
,
Hawley
CM
,
Cho
Y
, et al.
Associations between peritoneal glucose exposure, glucose degradation product exposure, and peritoneal membrane transport characteristics in peritoneal dialysis patients: secondary analysis of the balANZ trial
.
Perit Dial Int
.
2018 Sep–Oct
;
38
(
5
):
349
55
. .
11.
Williams
JD
,
Craig
KJ
,
Topley
N
,
Von Ruhland
C
,
Fallon
M
,
Newman
GR
, et al.
Morphologic changes in the peritoneal membrane of patients with renal disease
.
J Am Soc Nephrol
.
2002 Feb
;
13
(
2
):
470
9
.
12.
Inagi
R
,
Miyata
T
,
Yamamoto
T
,
Suzuki
D
,
Urakami
K
,
Saito
A
, et al.
Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis
.
FEBS Lett
.
1999 Dec
;
463
(
3
):
260
4
. .
13.
Nakayama
M
,
Miyazaki
M
,
Honda
K
,
Kasai
K
,
Tomo
T
,
Nakamoto
H
, et al.
Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study
.
Perit Dial Int
.
2014 Nov–Dec
;
34
(
7
):
766
74
. .
14.
Davenport
A
,
Willicombe
MK
.
Hydration status does not influence peritoneal equilibration test ultrafiltration volumes
.
Clin J Am Soc Nephrol
.
2009 Jul
;
4
(
7
):
1207
12
. .
15.
Konings
CJ
,
Kooman
JP
,
Schonck
M
,
Struijk
DG
,
Gladziwa
U
,
Hoorntje
SJ
, et al.
Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study
.
Nephrol Dial Transplant
.
2003 Apr
;
18
(
4
):
797
803
. .
16.
Brown
MC
,
Simpson
K
,
Kerssens
JJ
,
Mactier
RA
;
on behalf of the Scottish Renal Registry
.
Encapsulating peritoneal sclerosis in the new millennium: a national cohort study
.
Clin J Am Soc Nephrol
.
2009 Jul
;
4
(
7
):
1222
9
. .
17.
Johnson
DW
,
Cho
Y
,
Livingston
BE
,
Hawley
CM
,
McDonald
SP
,
Brown
FG
, et al.
Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes
.
Kidney Int
.
2010 May
;
77
(
10
):
904
12
. .
18.
Kawanishi
H
,
Kawaguchi
Y
,
Fukui
H
,
Hara
S
,
Imada
A
,
Kubo
H
, et al.
Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study
.
Am J Kidney Dis
.
2004 Oct
;
44
(
4
):
729
37
.
19.
Mehrotra
R
,
Duong
U
,
Jiwakanon
S
,
Kovesdy
CP
,
Moran
J
,
Kopple
JD
, et al.
Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis
.
Am J Kidney Dis
.
2011 Sep
;
58
(
3
):
418
28
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.